Travere Therapeutics: Pay

Travere Therapeutics paid its 5 named executives $18.3M in total in FY2025 (Dec). CEO Eric Dube, Ph.D. was paid $8.5M of that.

Pay$100 in the stock at the end of FY20 → $169
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Eric Dube, Ph.D.President, Chief Executive Officer and Director
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Jula Inrig, M.D.Chief Medical Officer
FY2025 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
3 years
Peter HeermaChief Commercial Officer
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
William E. Rote, Ph.D.Chief Research Officer
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Christopher ClineChief Financial Officer
FY2025 (Dec)
FY2022 (Dec)Not disclosed
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $10.9M. The CEO of Travere Therapeutics was paid $8.5M, 23% below the median.

  1. 1PTC Therapeutics
  2. 2Supernus Pharmaceuticals
  3. 3INSMED
  4. 4Ultragenyx Pharmaceutical
  5. 5Mirum Pharmaceuticals
  6. 6Travere Therapeutics
  7. 7Harmony Biosciences Holdings
  8. 8Agios Pharmaceuticals
  9. 9Collegium Pharmaceutical
  10. 10Amicus TherapeuticsNot disclosed
  11. 11Biocryst PharmaceuticalsNot disclosed
  12. 12Coherus BioSciences (now known as Coherus Oncology)Not disclosed
  13. 13Corcept TherapeuticsNot disclosed
  14. 14Dynavax TechnologiesNot disclosed
  15. 15Intercept PharmaceuticalsNot disclosed
  16. 16Ironwood PharmaceuticalsNot disclosed
  17. 17Ligand PharmaceuticalsNot disclosed
  18. 18PHATNot disclosed
  19. 19Pacira BioSciencesNot disclosed
  20. 20Phathom PharmaceuticalsNot disclosed
  21. 21Rhythm PharmaceuticalsNot disclosed
  22. 22Vanda PharmaceuticalsNot disclosed
  23. 23VericelNot disclosed
  24. 24Xeris Biopharma HoldingsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.